Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
MLTX
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
Earnings Growth
YoY
Current
Estimates
Q2.23
N/A
-0.23
vs -0.34
Q3.23
N/A
-0.18
vs -0.27
Q4.23
N/A
-0.12
vs -0.31
Q1.24
N/A
-0.22
vs -0.23
Q2.24
N/A
-0.39
vs -0.23
Q3.24
N/A
-0.56
vs -0.18
Q4.24
N/A
-0.72
vs -0.12
Q1.25
N/A
-0.63
vs -0.22
Q2.25
N/A
-0.72
vs -0.39
Q3.25
N/A
-0.74
vs -0.56
Sales Growth
YoY
Current
Estimates
Q4.22
NA
NA vs NA
Q1.23
NA
NA vs NA
Q2.23
NA
NA vs NA
Q3.23
NA
NA vs NA
Q4.23
NA
19.7K vs NA
Q1.24
NA
NA vs NA
Q2.24
NA
NA vs NA
Q3.24
NA
NA vs NA
Q4.24
+416%
101.8K vs 19.7K
Q1.25
NA
NA vs NA
Return on Equity
QoQ
Q2.23
-2%
-0.02
vs -0.29
Q3.23
-2%
-0.02
vs -0.02
Q4.23
-2%
-0.02
vs -0.02
Q1.24
-3%
-0.03
vs -0.02
Q2.24
-5%
-0.05
vs -0.03
Q3.24
-7%
-0.07
vs -0.05
Q4.24
0%
-0.00
vs -0.07
Q1.25
-10%
-0.10
vs -0.00
Institutionnal Ownership
QoQ
Q2.23
84
84
vs 43
95%
Q3.23
132
132
vs 84
57%
Q4.23
148
148
vs 132
12%
Q1.24
133
133
vs 148
-10%
Q2.24
119
119
vs 133
-11%
Q3.24
116
116
vs 119
-3%
Q4.24
126
126
vs 116
9%
Q1.25
148
148
vs 126
17%
zacks.com
13 hours ago
seekingalpha.com
15 hours ago
globenewswire.com
16 hours ago
globenewswire.com
16 hours ago
reuters.com
17 hours ago
Quote Panel
Key Metrics
Forecast
-478%2026-EPS
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Buy
Price Target
0.00(-100.00%)
Number of analyst
0
Last analyst upgrade/downgrade
Wolfe Research
upgradePrevious: Peer Perform
2025-05-19
Now: Outperform
Wolfe Research
downgradePrevious: Not converted
2024-08-26
Now: Peer Perform
Oppenheimer
initialisePrevious: Not converted
2024-06-24
Now: Outperform
Goldman Sachs
initialisePrevious: Not converted
2024-04-02
Now: Neutral
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.
NASDAQ
Unprofitable
Unprofitable
1.11 ( 2.58%)
Relative Strenght
60
Volume Buzz
-94%
Earning Acce
No
Dist 52w H.
24%Relative Strength
MLTX
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|